IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Boehringer Ingelheim
Astellas Pharma Inc
Amgen
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
ModernaTX, Inc.
Astellas Pharma Inc
Bristol-Myers Squibb
Isala
Vividion Therapeutics, Inc.
Erasca, Inc.
Eli Lilly and Company
University of California, San Diego
Wake Forest University Health Sciences
Rondo Therapeutics
Shenzhen Ionova Life Sciences Co., Ltd.
Vividion Therapeutics, Inc.
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
QuantumLeap Healthcare Collaborative
NeoImmuneTech
Revolution Medicines, Inc.
Hoffmann-La Roche
University of Ulm
Amgen
Dana-Farber Cancer Institute
Ankara Etlik City Hospital
Children's Hospital Medical Center, Cincinnati
Tizona Therapeutics, Inc
Essen Biotech
Nouscom SRL
University of California, San Diego
Werewolf Therapeutics, Inc.
Hoffmann-La Roche
Teva Branded Pharmaceutical Products R&D, Inc.
Cytovation AS
University of California, San Diego